Formycon (@formycon) header
Formycon (@formycon) profile picture

Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars.

Planegg, Deutschland
Joined January 2019
Photo by Formycon (@formycon)Photo by Formycon (@formycon)Photo by Formycon (@formycon)Photo by Formycon (@formycon)Photo by Formycon (@formycon)Photo by Formycon (@formycon)Photo by Formycon (@formycon)Photo by Formycon (@formycon)Photo by Formycon (@formycon)Photo by Formycon (@formycon)
๐’๐ก๐š๐ฉ๐ข๐ง๐  ๐ญ๐ก๐ž ๐ง๐ž๐ฑ๐ญ ๐ ๐ž๐ง๐ž๐ซ๐š๐ญ๐ข๐จ๐ง ๐จ๐Ÿ ๐…๐˜๐ ๐›๐ข๐จ๐ฌ๐ข๐ฆ๐ข๐ฅ๐š๐ซ๐ฌ. Today we published our nine-month results for 2026, which show significant operational successes and a clear improvement in revenue and operating income compared to the same period last year.
13
Formycon invites to Conference Call on 2026 Nine-Month Results. To join the earnings call on November 12, please use the following link: webcast-eqs.com/formycon-202โ€ฆ
83
โ€œWe believe that PK-focused clinical approaches have the potential to reshape biosimilar development in a lasting way,โ€ says Dr Andreas Seidl, CSO of Formycon: lnkd.in/ebzuA4vD
1
97
Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-year formycon.com/en/investor-relโ€ฆ
1
54
Formycon invites to conference call on 2026 half-year results: webcast-eqs.com/formycon-202โ€ฆ
53
In the #NebenwerteWelt podcast, Formycon CFO Enno Spillner shares insights on the basics of #biosimilars and what makes the dynamic biosimilar market so attractive youtu.be/xWkjpQK9FOI?si=BLJ4โ€ฆ
1
42
Formycon reports positive operational Progress and strong Revenue Growth in the First Quarter of 2026 formycon.com/en/blog/press-rโ€ฆ
1
3
72
Formycon invites to conference call on the results of the first quarter of 2026. The conference call will take place on Thursday, May 28, 2026, at 3:00 PM (CEST) in English: webcast-eqs.com/formycon-202โ€ฆ
2
178
๐…๐จ๐ซ๐ฆ๐ฒ๐œ๐จ๐งโ€™๐ฌ ๐š๐Ÿ๐ฅ๐ข๐›๐ž๐ซ๐œ๐ž๐ฉ๐ญ ๐›๐ข๐จ๐ฌ๐ข๐ฆ๐ข๐ฅ๐š๐ซ๐ฌ ๐ฅ๐š๐ฎ๐ง๐œ๐ก๐ž๐ ๐ข๐ง ๐„๐ฎ๐ซ๐จ๐ฉ๐ž: formycon.com/en/blog/press-rโ€ฆ
1
2
133
For information on the 2025 financial results and the outlook for 2026, please refer to our corporate news: formycon.com/en/blog/press-rโ€ฆ For full details on the financial results, please refer to the Annual Report on our website: formycon.com/wp-content/uploโ€ฆ
1
45
๐‚๐จ๐ง๐Ÿ๐ž๐ซ๐ž๐ง๐œ๐ž ๐‚๐š๐ฅ๐ฅ ๐จ๐ง ๐ญ๐ก๐ž ๐‘๐ž๐ฌ๐ฎ๐ฅ๐ญ๐ฌ ๐Ÿ๐จ๐ซ ๐ญ๐ก๐ž ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“ ๐…๐ข๐ฌ๐œ๐š๐ฅ ๐˜๐ž๐š๐ซ To follow the conference live, please register via the following link: webcast-eqs.com/formycon-202โ€ฆ Access the replay at: formycon.com/en/investor-relโ€ฆ
28
The European Biotechnology Science & Industry Guide is more than just a โ€œWho's Whoโ€ of European biotechnology. It also highlights current developments in innovation, deals and financing. With its biosimilar projects, Formycon is happy to be featured in the current edition.
51
๐…๐จ๐ซ๐ฆ๐ฒ๐œ๐จ๐ง ๐ฌ๐ž๐œ๐ฎ๐ซ๐ž๐ฌ ๐ฅ๐ข๐œ๐ž๐ง๐ฌ๐ž ๐๐š๐ญ๐ž ๐Ÿ๐จ๐ซ ๐…๐˜๐๐Ÿ๐ŸŽ๐Ÿ‘ ๐ข๐ง ๐„๐ฎ๐ซ๐จ๐ฉ๐ž ๐š๐ง๐ ๐Ÿ๐ฎ๐ซ๐ญ๐ก๐ž๐ซ ๐ญ๐ž๐ซ๐ซ๐ข๐ญ๐จ๐ซ๐ข๐ž๐ฌ Market launches by commercialization partners across Europe to start in May 2026 formycon.com/en/blog/press-rโ€ฆ
71
๐Ÿ”ฌ Dahlia study demonstrates PK equivalence of FYB206 with the reference drug Keytrudaยฎ formycon.com/en/blog/press-rโ€ฆ
1
1
86
We are happy to announce another milestone in our global commercialization journey for FYB206: formycon.com/en/blog/press-rโ€ฆ
4
159
The FDA has approved Nufymcoยฎ, another interchangeable #ranibizumab #biosimilar in the U.S., underscoring Formyconโ€™s pioneering position in high-quality biosimilar #development: formycon.com/en/blog/press-rโ€ฆ
2
101
Zydus Lifesciences Limited to commercialize Formyconโ€™s Keytruda biosimilar FYB206 in the US and Canada: formycon.com/en/blog/press-rโ€ฆ
1
116
Formycon starts commercial partnering activities for #FYB206: MS Pharma will commercialize the Keytrudaยฎ biosimilar candidate in the #MENA region: formycon.com/en/blog/press-rโ€ฆ
2
102
Immunological Dupilumab Biosimilar Candidate FYB208 as another growth driver in Formycon's portfolio formycon.com/en/blog/press-rโ€ฆ
2
144